All posts
-
Press Coverage — April 12, 2023
Breakthrough that could put an end to invasive surgery for rectal cancer patients
-
Press Releases — April 10, 2023
C2i Genomics Study Finds Circulating Tumor DNA Can Predict Treatment Outcomes in Patients with Locally Advanced Rectal Cancer Enrolled for Organ Preservation
-
Press Coverage — March 3, 2023
C2i Genomics, Riken Genesis to expand AI-powered whole-genome MRD cancer detection technology across Japan
-
Press Coverage — March 3, 2023
C2i Genomics, Riken Genesis expand AI-powered cancer detection technology across Japan
-
Press Coverage — March 3, 2023
C2i Genomics Expands to Japan, Announces Collab with Riken Genesis
-
Press Releases — March 2, 2023
C2i Genomics and Riken Genesis to Expand AI-Powered Whole-Genome MRD Cancer Detection Technology Across Japan
-
Press Coverage — March 2, 2023
C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan
-
Press Coverage — January 17, 2023
C2i Genomics Announces Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer Models; Company Will Collaborate with AstraZeneca to Explore the C2i Minimal Residual Disease (MRD) Test for Clinical Research & Drug Development
-
Press Coverage — January 6, 2023
C2i Genomics extends AstraZeneca cancer deal
-
Press Coverage — January 6, 2023
C2i Genomics, AstraZeneca to collaborate on MRD test for clinical R&D